|
Variable (LO/HI)
|
Control OS
|
Anti-PD-1 OS
|
|---|
|
Univariable analysis
|
Univariable analysis
|
Multivariablea analysis per variable
|
Multivariablea analysis with Thy1, SMA, FAP
|
|---|
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Thy1+/total
|
1.65 (0.87–2.88)
|
0.12
|
4.66 (2.34–8.82)
|
< 0.0001
|
4.67 (2.19–9.53)
|
0.0001
|
3.02 (1.44–6.10)
|
0.0044
|
|
SMA+/Thy1+
|
0.45 (0.22–1.07)
|
0.070
|
0.34 (0.18–0.68)
|
0.0029
|
0.32 (0.16–0.67)
|
0.0027
|
0.62 (0.30–1.31)
|
0.20
|
|
FAP+/Thy1+
|
0.57 (0.37–0.88)
|
0.012
|
4.11 (2.05–9.14)
|
< 0.0001
|
4.64 (2.27–10.52)
|
< 0.0001
|
3.61 (1.65–8.56)
|
0.0011
|
- Abbreviations: CAF cancer-associated fibroblast, CI confidence interval, HI high, HR hazard ratio, LO low, OS overall survival
- aCox proportional hazards model included age, sex, mutation status, stage, treatment, and prior immune checkpoint blockade as covariates
